In DLBCL, TP53 mutations are found in ∼20% of cases and are significantly and independently associated with poor overall survival of both activated B‐cell like (ABC) and germinal centre B‐cell like (GCB) DLBCL treated with R‐CHOP 22, 23. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.